We previously identified TRIM28 as a direct interactor of the Androgen Receptor in prostate cancer cells, critically involved in prostate cancer cell proliferation. This study will: 1. identify the functional contribution of TRIM28 on Androgen Receptor function in prostate cancer cells, 2. Unravel the underlying basis of the observed genomic selectivity, 3. Reveal the clinical implications of TRIM28 on prostate cancer patient outcome and response to therapy, and 4. Expose how this TRIM28/AR interaction could be therapeutically exploited in the treatment of prostate cancer patients.
Determining the role TRIM28 in hormone- dependent prostate cancer